Influnence Of The Treatment Of Jianpi Jiedu On T-lymphocyte Subsets And Quality Of Life In Patients With Primary Liver Cancer After TACE

Objective:By observing the effect of Jianpi Jiedu Decoction on T-cell subsets, symptoms,biochemical indicators,tumor imaging,and quality of life of patients with primary hepatocellular carcinoma after TACE,it provides evidence-based basis for clinical treatment of primary liver cancer.Methods:From January 2016 to December 2017,60 inpatients in the Department of Gastroenterology of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine were selected.The patients were randomly divided into a control group and a treatment group with 30 patients in each group.The two groups of patients were given TACE,active control of the primary disease,liver protection and other Western medical treatment programs,and the treatment group in combination with the above treatment program based on the use of Jianpi Jiedu Fang,a course of 2months.After the end of treatment,statistical analysis was performed on the changes of CD3+,CD4+,CD8+,AFP,clinical symptoms,Tumor imaging evaluation,and quality of life in both groups.Results:1.After treatment,the levels of CD3~+ and CD4~+ T cells in the two groups increased to different degrees before treatment;the difference was statistically significant in the treatment group(P<0.05);there was no significant difference in the control group(P>0.05);The levels of CD3~+ and CD4~+ T cells in the group after treatment were statistically different(P<0.05).2.After treatment,the levels of CD8~+ T cells in both groups decreased;there was no significant difference between the treatment group and the control group(P>0.05);there was no statistical difference in the level of CD8~+ T cells between the groups after treatment(P>0.05).3.After treatment,the AFP levels in the two groups were significantly reduced.There was a statistically significant difference between the two groups(P<0.05).There was a statistically significant difference between the two groups after treatment(P<0.05).4.The discomfort of the two groups was relieved after treatment;there was significant difference between the two groups before and after treatment(P<0.05);there was no significant difference between the two groups after treatment(P>0.05).5.The quality of life scores before and after treatment were compared between the two groups.The treatment group increased after treatment and the control group did not change significantly.There was a statistical difference between the intra-group contrast treatment group(P<0.05)and no statistical difference between the control group(P>0.05).There was a statistically significant difference between the two groups after treatment(P<0.05).6.After the treatment of the two groups,the tumor lesions were significantly smaller than before.There was a statistically significant difference between the two groups(P<0.05).Conclusions:1.Jianpi Jiedu Fang can improve the level of CD3~+ and CD4~+ and reduce the level of CD8~+ in patients with primary liver cancer after TACE.2.Jianpi Jiedu Fang combined with basic medical treatment of the western medicine can better reduce the AFP level of patients with Primary Liver Cancer after TACE.3.Jianpi Jiedu Fang combined with basic medical treatment of the western medicine on the efficacy of lesion imaging evaluation than the control group.4.The combination of Jianpi Jiedu Decoction and Western medicine can better improve the symptoms of patients with liver cancer after TACE and improve the quality of life of patients.